Bayer reported that its oral factor XIa inhibitor asundexian met the primary endpoint in a phase III trial, cutting the risk of recurrent ischemic stroke without increasing major bleeding. The company said detailed efficacy and safety data will be presented at a forthcoming scientific congress and discussed with regulators ahead of potential approvals. Investors reacted strongly: Bayer shares jumped more than 12% on the topline release. The result represents a rare late‑stage success for the FXIa inhibitor class after a string of recent setbacks and revives interest in oral anticoagulant programs aimed at reducing thrombosis while limiting bleeding risk. Bayer’s readout will be watched for subgroup signals and safety details; competing FXIa programs — including milvexian and abelacimab — are now positioned to highlight class momentum in stroke prevention.